bendamustine
bendamustine: 38 clinical trials tracked.
bendamustine evidence translation
What we can confirm
38 tracked trials
What it means
What to watch
Prepared research question
What is verified about bendamustine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 15 study sponsors
Related indications
Clinical Trials (38)showing 10 most recent
A Phase 2/3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma
Primary endpoint: Part 1: Number of Participants Who Experience an Adverse Event (AE)
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors
Primary endpoint: Progression-Free Survival (PFS) by IRC
A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
Primary endpoint: Progression-free Survival (PFS) as assessed by the Independent Review Committee (IRC)
A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
Primary endpoint: Complete Response Rate (CRR) after 1-year of Maintenance Treatment
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
Primary endpoint: Progression-Free Survival (PFS) by Independent Review Committee (IRC)
A Phase 2 Multicenter Study of the Combination Zanubrutinib, Bendamustine, and Rituximab in Previously Untreated Waldenström Macroglobulinemia (ZEBRA Trial)
Primary endpoint: Very Good Partial Response (VGPR) or Better Response Rate
A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL)
Primary endpoint: Progression-free survival (PFS)
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Primary endpoint: Number of participants with treatment-emergent adverse events (TEAEs)
Phase 1a/1b Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells (MC10029) in Subjects With Relapsed or Refractory BAFFR-Expressing B-Cell Hematologic Malignancies
Primary endpoint: Incidence of dose-limiting toxicities (DLT)
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Primary endpoint: Arm A1 vs Arm B: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)